<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04770623</url>
  </required_header>
  <id_info>
    <org_study_id>360</org_study_id>
    <nct_id>NCT04770623</nct_id>
  </id_info>
  <brief_title>Docetaxel and Irinotecan in Gastric Cancer</brief_title>
  <official_title>Docetaxel and Irinotecan Combination as a Second Line Treatment of Metastatic Gastric Cancer; a Phase II Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Menoufia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Menoufia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the role of docetaxel and irinotecan combination in second line gastric cancer. The&#xD;
      primary end point is response rate. Secondary end points are toxicity, PFS and OS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gastric cancer is a major killer in oncology. The expected overall survival of metastatic&#xD;
      patients is less than 2 years. Moreover, most of the patients develop cachexia and worsening&#xD;
      of performance over time. As a result, many patients are not fit for second line treatment&#xD;
      when eligible. There is currently no approved consensus for third line treatment regimen and&#xD;
      in most of the patients it is usually best supportive care.&#xD;
&#xD;
      Irinotecan and docetaxel were tested as single agents or in combination with other drugs&#xD;
      (e.g. FOLFIRI) in second line setting. However, the combination of these two drugs together&#xD;
      was not tested before. Both agents are active in second line setting which is considered the&#xD;
      last chance of the patient in view of lack of evidence in third line setting.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 5, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Patients from multiple oncology centers across Egypt are recruited for this study. Second line treatment of advanced gastric cancer will be tested with irinotecan and docetaxel combination</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>6 months from chemotherapy</time_frame>
    <description>described according to RECIST criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL)</measure>
    <time_frame>three months and six months from chemotherapy</time_frame>
    <description>A questionnaire with the QLQ-C30 form will be conducted at enrollment, after 3 months and after end of treatment.&#xD;
A score between 1 to 4 will be used in the questionnaire where higher score means worse quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>One year from start of enrollment</time_frame>
    <description>The time interval between starting the test protocol and the next disease progression or death whichever earlier</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>One year from start of enrollment</time_frame>
    <description>The time interval between diagnosis and death</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Stomach Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Chemotherapy Effect</condition>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Second line treatment will be as follows&#xD;
Docetaxel at 30 mg/m2 over 500 cc normal saline over 1 hour infusion&#xD;
Irinotecan at 185 mg/m2 with a maximum of 300 mg given over 500 cc normal saline over 2 hours infusion&#xD;
The whole regimen is to be cycled every 2 weeks for a maximum of 6 months with interim and end of treatment evaluation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>patients with gastric cancer who have disease progression after first line treatment will receive the test protocol and evaluated for efficacy and survival</description>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>patients with gastric cancer who have disease progression after first line treatment will receive the test protocol and evaluated for efficacy and survival</description>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histopathological evidence of adenocarcinoma of the stomach&#xD;
&#xD;
          -  Metastatic disease or locally advanced non-resectable disease&#xD;
&#xD;
          -  Patients who received only one line of treatment&#xD;
&#xD;
          -  Performance status 0,1,2 as per ECOG scoring system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who received docetaxel or irinotecan before recruitment to this study&#xD;
&#xD;
          -  Multiple comorbid conditions&#xD;
&#xD;
          -  Liver or kidney impairment&#xD;
&#xD;
          -  Severe cachexia (sarcopenia)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ahmed Sohaib, PhD</last_name>
    <phone>+201060406063</phone>
    <email>dr.ahmed.sohaib@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Reham A Abdel Aziz, PhD</last_name>
    <phone>+201006674714</phone>
    <email>reham.ahmed@med.menfia.edu.eg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Menoufia University, Faculty of medicine</name>
      <address>
        <city>ShibÄ«n Al Kawm</city>
        <state>Menoufia</state>
        <zip>32511</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed Sohaib, PhD</last_name>
      <phone>01060406063</phone>
      <email>dr.ahmed.sohaib@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Amira H Hegazy, PhD</last_name>
      <phone>01090432337</phone>
      <email>amira.hosney.12@med.menofia.edu.eg</email>
    </contact_backup>
    <investigator>
      <last_name>Reham A Abdel Aziz, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alexandria University</name>
      <address>
        <city>Alexandria</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed Elshazly, PhD</last_name>
      <phone>+201129090109</phone>
      <email>mohammed.elshazly@alexmed.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Assiut University</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ereny Samwel, MD</last_name>
      <phone>+201000470421</phone>
      <email>erenysamwel@aun.edu.eg</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ain Shams University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nermeen Bahi Eldin, PhD</last_name>
      <phone>+201229000721</phone>
      <email>nermean.mostafa@med.asu.edu.eg</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cairo University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Riham H Radwan, PhD</last_name>
      <phone>+201005047002</phone>
      <email>rihamhany@kasralainy.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Catalano V, Graziano F, Santini D, D'Emidio S, Baldelli AM, Rossi D, Vincenzi B, Giordani P, Alessandroni P, Testa E, Tonini G, Catalano G. Second-line chemotherapy for patients with advanced gastric cancer: who may benefit? Br J Cancer. 2008 Nov 4;99(9):1402-7. doi: 10.1038/sj.bjc.6604732.</citation>
    <PMID>18971936</PMID>
  </reference>
  <reference>
    <citation>Shitara K, Muro K, Shimada Y, Hironaka S, Sugimoto N, Komatsu Y, Nishina T, Yamaguchi K, Segawa Y, Omuro Y, Tamura T, Doi T, Yukisawa S, Yasui H, Nagashima F, Gotoh M, Esaki T, Emig M, Chandrawansa K, Liepa AM, Wilke H, Ichimiya Y, Ohtsu A. Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer. Gastric Cancer. 2016 Jul;19(3):927-38. doi: 10.1007/s10120-015-0559-z. Epub 2015 Oct 28.</citation>
    <PMID>26510663</PMID>
  </reference>
  <reference>
    <citation>Tetzlaff ED, Cheng JD, Ajani JA. Review of docetaxel in the treatment of gastric cancer. Ther Clin Risk Manag. 2008 Oct;4(5):999-1007.</citation>
    <PMID>19209281</PMID>
  </reference>
  <reference>
    <citation>Farhat FS. A general review of the role of irinotecan (CPT11) in the treatment of gastric cancer. Med Oncol. 2007;24(2):137-46. Review.</citation>
    <PMID>17848736</PMID>
  </reference>
  <reference>
    <citation>Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, Dogan Y, Gebauer B, Schumacher G, Reichardt P. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011 Oct;47(15):2306-14. doi: 10.1016/j.ejca.2011.06.002.</citation>
    <PMID>21742485</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 19, 2021</study_first_submitted>
  <study_first_submitted_qc>February 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2021</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Menoufia University</investigator_affiliation>
    <investigator_full_name>Ahmed Sohaib</investigator_full_name>
    <investigator_title>Principal investigator, Lecturer of Clinical oncology</investigator_title>
  </responsible_party>
  <keyword>gastric</keyword>
  <keyword>stomach</keyword>
  <keyword>docetaxel</keyword>
  <keyword>irinotecan</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>second line</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Investigators of this study agreed to share IPD for free with any other investigators with the following conditions:&#xD;
Sharing the data will be after publishing the primary results&#xD;
Other studies using our data should submit our names as sub-investigators when publishing their results.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Sharing the data will be after publishing the primary results, expected to be by the end 0f 2022</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

